Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: The DEFINE study

Current Cardiovascular Risk Reports

Volumn 5, Issue 2, 2011, Pages 109-112

  Lewis, Cora Elizabeth ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TORCETRAPIB;

ADULT; AGED; ARTICLE; BAYES THEOREM; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; FRAMINGHAM RISK SCORE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

EID: 84873493526     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-011-0159-3     Document Type: Article

References (7)

1. Grundy SM, Cleeman JI, Bairey-Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004; 110: 227-39.
2. Barter PJ, Caulfield M, Eriksson M, et al. Effects of Torcetrapib in patients at high risk for coronary events. New Engl J Med. 2007; 357: 2109-22.
3. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009; 157: 352-60. e2.
4. Cannon CP, Dansky HM, Davidson M, et al. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009; 158: 513-519. e3.
5. Thompson A, Di Angelantonio E, Sarwar N. et al Association of cholesterol ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008; 299: 2777-88.
6. Yvan-Charvet L, Kling J, Pagler T, et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol. 2010; 30: 1430-8.
7. Gurfinkel R, Joy TR. Anacetrapib: Hope for CETP Inhibitors? Cardiovasc Ther. 2010 Apr 9. [Epub ahead of print].